Is VTVT or EVAX more profitable?

vTv Therapeutics' return on equity of 3.96% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A 3.96% 2.86% Evaxion A/S N/A -73.56% -37.45%

Do analysts prefer EVAX or THAR?

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 169.28%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion A/S is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVAX or THAR more profitable?

Evaxion A/S's return on equity of -73.56% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Tharimmune N/A -588.45% -264.41%

Is EVAX or RANI more profitable?

Evaxion A/S's return on equity of -73.56% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Rani Therapeutics N/A -206.46% -83.95%

Which has preferable earnings & valuation, EVAX or GNLX?

Evaxion A/S has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evaxion A/S $7.53M 4.52 -$7.71M -$1.47 N/A Genelux $10K 13,680.68 -$32.15M -$0.85 N/A

Is EVAX or GNLX more profitable?

Evaxion A/S's return on equity of -73.56% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Genelux N/A -174.55% -123.65%

Is EVAX or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Black Diamond Therapeutics N/A -30.18% -23.91%

Evaxion A/S (EVAX) Competitors

$4.08 -0.02 (-0.37%)

As of 01:22 PM Eastern

Compare

EVAX vs. VTVT, THAR, RANI, GNLX, and BDTX

Should you buy Evaxion A/S stock or one of its competitors? MarketBeat compares Evaxion A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evaxion A/S include vTv Therapeutics (VTVT), Tharimmune (THAR), Rani Therapeutics (RANI), Genelux (GNLX), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Evaxion A/S compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Evaxion A/S has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	126.68	-$26.97M	-$0.93	N/A
Evaxion A/S	$7.53M	4.52	-$7.71M	-$1.47	N/A

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

vTv Therapeutics' return on equity of 3.96% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
Evaxion A/S	N/A	-73.56%	-37.45%

In the previous week, vTv Therapeutics and vTv Therapeutics both had 1 articles in the media. vTv Therapeutics' average media sentiment score of 1.89 beat Evaxion A/S's score of 1.87 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Very Positive
Evaxion A/S	Very Positive

vTv Therapeutics presently has a consensus target price of $53.00, suggesting a potential upside of 61.61%. Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 169.28%. Given Evaxion A/S's higher probable upside, analysts plainly believe Evaxion A/S is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

vTv Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Summary

vTv Therapeutics beats Evaxion A/S on 8 of the 13 factors compared between the two stocks.

How does Evaxion A/S compare to Tharimmune?

Evaxion A/S (NASDAQ:EVAX) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, Evaxion A/S had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Evaxion A/S and 0 mentions for Tharimmune. Evaxion A/S's average media sentiment score of 1.87 beat Tharimmune's score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Tharimmune	Neutral

Evaxion A/S's return on equity of -73.56% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Tharimmune	N/A	-588.45%	-264.41%

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than Tharimmune. Evaxion A/S is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.52	-$7.71M	-$1.47	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 169.28%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion A/S is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Evaxion A/S beats Tharimmune on 12 of the 14 factors compared between the two stocks.

How does Evaxion A/S compare to Rani Therapeutics?

Evaxion A/S (NASDAQ:EVAX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Rani Therapeutics had 3 more articles in the media than Evaxion A/S. MarketBeat recorded 4 mentions for Rani Therapeutics and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.87 beat Rani Therapeutics' score of 0.82 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Rani Therapeutics	Positive

Evaxion A/S's return on equity of -73.56% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Rani Therapeutics	N/A	-206.46%	-83.95%

Evaxion A/S currently has a consensus target price of $11.00, suggesting a potential upside of 169.28%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 791.04%. Given Rani Therapeutics' higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Evaxion A/S has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Evaxion A/S has higher revenue and earnings than Rani Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.52	-$7.71M	-$1.47	N/A
Rani Therapeutics	$1.63M	74.63	-$29.67M	-$0.41	N/A

Summary

Evaxion A/S beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to Genelux?

Evaxion A/S (NASDAQ:EVAX) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Evaxion A/S's return on equity of -73.56% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Genelux	N/A	-174.55%	-123.65%

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Evaxion A/S has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.52	-$7.71M	-$1.47	N/A
Genelux	$10K	13,680.68	-$32.15M	-$0.85	N/A

Evaxion A/S has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Genelux has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 169.28%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 489.97%. Given Genelux's higher probable upside, analysts plainly believe Genelux is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Genelux had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 2 mentions for Genelux and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.87 beat Genelux's score of 0.94 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Genelux	Positive

Summary

Evaxion A/S beats Genelux on 9 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to Black Diamond Therapeutics?

Evaxion A/S (NASDAQ:EVAX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 2 mentions for Black Diamond Therapeutics and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.87 beat Black Diamond Therapeutics' score of 0.66 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Black Diamond Therapeutics	Positive

Black Diamond Therapeutics' return on equity of -30.18% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

Black Diamond Therapeutics has higher revenue and earnings than Evaxion A/S. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.52	-$7.71M	-$1.47	N/A
Black Diamond Therapeutics	$70M	1.85	$22.37M	-$0.77	N/A

Evaxion A/S currently has a consensus target price of $11.00, suggesting a potential upside of 169.28%. Black Diamond Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 341.50%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Evaxion A/S has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.34, indicating that its stock price is 234% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Evaxion A/S on 12 of the 16 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVAX vs. The Competition

Export

Metric	Evaxion A/S	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.07M	$1.55B	$6.42B	$12.60B
Dividend Yield	N/A	N/A	2.75%	5.26%
P/E Ratio	-2.78	78.28	21.28	26.32
Price / Sales	4.52	6.68	558.91	114.49
Price / Cash	N/A	22.51	43.49	56.90
Price / Book	2.59	7.48	10.60	7.34
Net Income	-$7.71M	-$54.76M	$3.56B	$337.06M
7 Day Performance	0.12%	1.04%	3.21%	3.67%
1 Month Performance	-4.11%	10.87%	6.51%	7.41%
1 Year Performance	77.61%	-0.10%	36.74%	37.93%

Evaxion A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVAX Evaxion A/S	3.9141 of 5 stars	$4.09 -0.4%	$11.00 +169.3%	+55.9%	$34.07M	$7.53M	N/A	60
VTVT vTv Therapeutics	3.1596 of 5 stars	$33.16 -3.6%	$53.00 +59.8%	+100.6%	$135.52M	$36.84M	N/A	9
THAR Tharimmune	N/A	$3.52 +5.1%	N/A	+128.3%	$132.81M	N/A	N/A	2	Upcoming Earnings
RANI Rani Therapeutics	3.1967 of 5 stars	$0.94 -12.1%	$8.75 +830.4%	+53.3%	$132.55M	$1.63M	N/A	110	High Trading Volume
GNLX Genelux	2.8241 of 5 stars	$3.01 +3.1%	$18.00 +498.0%	+25.3%	$130.93M	$10K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVAX) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evaxion A/S (EVAX) Competitors

EVAX vs. VTVT, THAR, RANI, GNLX, and BDTX

How does Evaxion A/S compare to vTv Therapeutics?

Summary

How does Evaxion A/S compare to Tharimmune?

Summary

How does Evaxion A/S compare to Rani Therapeutics?

Summary

How does Evaxion A/S compare to Genelux?

Summary

How does Evaxion A/S compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evaxion A/S (EVAX) Competitors

EVAX vs. VTVT, THAR, RANI, GNLX, and BDTX

How does Evaxion A/S compare to vTv Therapeutics?

Which has stronger earnings & valuation, VTVT or EVAX?

Do institutionals & insiders have more ownership in VTVT or EVAX?

Is VTVT or EVAX more profitable?

Does the media favor VTVT or EVAX?

Do analysts prefer VTVT or EVAX?

Which has more volatility & risk, VTVT or EVAX?

Summary

How does Evaxion A/S compare to Tharimmune?

Does the media refer more to EVAX or THAR?

Is EVAX or THAR more profitable?

Do insiders & institutionals hold more shares of EVAX or THAR?

Which has preferable earnings and valuation, EVAX or THAR?

Which has more risk and volatility, EVAX or THAR?

Do analysts prefer EVAX or THAR?

Summary

How does Evaxion A/S compare to Rani Therapeutics?

Do insiders and institutionals have more ownership in EVAX or RANI?

Does the media favor EVAX or RANI?

Is EVAX or RANI more profitable?

Do analysts rate EVAX or RANI?

Which has more risk & volatility, EVAX or RANI?

Which has higher earnings and valuation, EVAX or RANI?

Summary

How does Evaxion A/S compare to Genelux?

Is EVAX or GNLX more profitable?

Do insiders & institutionals have more ownership in EVAX or GNLX?

Which has preferable earnings & valuation, EVAX or GNLX?

Which has more volatility & risk, EVAX or GNLX?

Do analysts rate EVAX or GNLX?

Does the media favor EVAX or GNLX?

Summary

How does Evaxion A/S compare to Black Diamond Therapeutics?

Does the media refer more to EVAX or BDTX?

Is EVAX or BDTX more profitable?

Which has stronger valuation & earnings, EVAX or BDTX?

Do analysts rate EVAX or BDTX?

Do institutionals and insiders have more ownership in EVAX or BDTX?

Which has more volatility and risk, EVAX or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools